Last reviewed · How we verify
A Phase 1 Safety and PK Study of IV TP-271
This is a single-center, randomized, placebo-controlled, double-blind, multiple-ascending-dose, inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy subjects. Subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study.
Details
| Lead sponsor | Tetraphase Pharmaceuticals, Inc |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 40 |
| Start date | Wed Aug 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Bacterial Infections
Interventions
- TP-271
- Placebo
Countries
United States